The State Trading Organization (STO) has officially launched Symbicort Turbuhaler and Pulmicort Respules in the Maldives, in partnership with AstraZeneca.
According to STO, these innovative products are integral to the management of asthma and COPD, addressing critical aspects of respiratory health.
The launching event was held in Dharumavantha Hospital on Sunday, bringing together nearly 60 physicians, and fostering discussions on guideline-directed treatments to enhance patient outcomes.
The launch event featured a keynote address by Dr. Rennis Davis, a renowned pulmonologist from India, who emphasized the significance of the GINA (Global Initiative for Asthma) guidelines in asthma and COPD management. Dr. Rennis Davis highlighted on the GINA guideline in Asthma and COPD that emphasizes reducing the overuse of SABA alone and drives maintenance and reliever management.
Symbicort Turbuhaler, an advanced dry powder inhaler, is designed for ease of use and offers fast, superior, and convenient relief compared to traditional SABA relievers. Pulmicort Respules, on the other hand, rapidly dissolve through the airway mucus layer within six minutes and deliver a strong pulmonary vasoconstrictive effect in just 30 minutes. This mechanism effectively reduces asthma symptoms with lower risks of exacerbation, making it a highly efficient alternative to systemic steroids.
STO said the organization takes pride in introducing revolutionary healthcare solutions that address critical medical needs, reaffirming its commitment to enhancing the quality of care for the Maldivian community.
